Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer

Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: A meta-analysis

(2014) Malaka Ameratunga et al.   Asia-Pacific Journal of Clinical Oncology

EGFR Blockade Enriches for Lung Cancer Stem-like Cells through Notch3-Dependent Signaling

(2014) R. R. Arasada et al.   CANCER RESEARCH

Lung Cancer Stem Cells and Implications for Future Therapeutics

(2014) Jing Wang et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer

(2014) A Zeuner et al.   CELL DEATH AND DIFFERENTIATION

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?

(2014) Paola Ulivi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

(2014) Vanesa Gregorc et al.   LANCET ONCOLOGY

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy

(2013) Sabrina Vari et al.   Expert Opinion on Drug Discovery

Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer

(2013) Scott A. Laurie et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

(2013) Tianhong Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts

(2013) Giovanni Sette et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Lung Cancer Stem Cell: Fancy Conceptual Model of Tumor Biology or Cornerstone of a Forthcoming Therapeutic Breakthrough?

(2013) Tony Sourisseau et al.   Journal of Thoracic Oncology

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

(2013) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Lung cancer-initiating cells: a novel target for cancer therapy

(2013) Brian J. Morrison et al.   Targeted Oncology

KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

(2012) Ji-lin Guan et al.   ANNALS OF SURGICAL ONCOLOGY

Advances in Treatment of Lung Cancer With Targeted Therapy

(2012) Philip T. Cagle et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer

(2012) Takashi Kobayashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Personalized Targeted Therapy for Lung Cancer

(2012) Kehua Wu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Tabulated Summary of Targeted and Biologic Therapies for Non–Small-Cell Lung Cancer

(2012) Neeta Somaiah et al.   Journal of Thoracic Oncology

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy

(2012) Michele Milella et al.   Journal of Thoracic Oncology

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential

(2012) Giovanni Sette et al.   PLoS One

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

(2011) E. Bria et al.   ANNALS OF ONCOLOGY

Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy

(2011) M Bartucci et al.   CELL DEATH AND DIFFERENTIATION

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy

(2010) Adi F. Gazdar   CANCER AND METASTASIS REVIEWS

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama Lung Cancer Study Group Trial 0705

(2010) Hiroshige Yoshioka et al.   Journal of Thoracic Oncology

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Lung cancer stem cells: tools and targets to fight lung cancer

(2010) A Eramo et al.   ONCOGENE

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

(2009) Rafael Rosell et al.   PLoS One

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment

(2009) G. Bertolini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells

(2008) Yu-Chih Chen et al.   PLoS One